Sign in Membership

Strategic Intelligence on China’s Health Policy, Coverage, and Financing System

Helping life sciences leaders navigate China’s health policy, coverage, and financing complexity for medical technologies — and translate system change into clearer access strategy and better-informed commercial decisions.

Published in Caixin and China Reform Magazine

Explore Access360

Engagement Paths

Access360

Ongoing intelligence to help life sciences decision-makers navigate China access decisions across health policy, coverage, financing, and implementation uncertainty.

Access monthly member intelligence, archives, member Q&A on published briefings, and the annual system-wide outlook.

→ Explore Access360

NRDL+ Masterclass

Executive strategic foundation for China access decision-making.

Through structured interpretation and guided case application, participants connect system-level signals to strategic trade-offs and execution constraints in China’s evolving coverage landscape.

→ Explore NRDL+ Masterclass

Latest Access360 Briefings

May 15, 2026

China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline

China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
Apr 09, 2026

China’s Healthcare System Is Reorganizing: What It Means for Manufacturers

As China’s healthcare system reorganizes, evolving care pathways and payment dynamics are reshaping how access is secured and how value is realized.
Mar 12, 2026

RWE and the Quiet Rewiring of China’s Reimbursement System

Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Feb 12, 2026

Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma

China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
Jan 14, 2026

From Reference Tool to Operating Model: A Roadmap for China’s C-List

China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
Dec 15, 2025

China Establishes Market-Price Database, Reshaping Global Pricing Signals

China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.